# Sunshine Lake Pharma Co., Ltd, Dongguan, China – FDA Inspections

Source: https://www.keypedia.com/companies/sunshine-lake-pharma-co-ltd/f256b8e6-f6d3-4011-8a94-3fdb7ffcb363

> Inspection records and compliance data for Sunshine Lake Pharma Co., Ltd in Dongguan. 8 FDA inspections on record (1 OAI), 3 Form 483s, last inspected March 22, 2024.

---

## Details

- Name: Sunshine Lake Pharma Co., Ltd
- FEI Number: 3007721552
- Business Operations: FDF MANUFACTURE
- Address Line 1: Northern Industry Road #1, Song Shan Lake
- City: Dongguan
- Country Name: China
- Address: Northern Industry Road #1, Song Shan Lake, Dongguan, China
- Country: China

## Related Documents

- [483 - Sunshine Lake Pharma Co., Ltd - 2024-03-22](https://www.keypedia.com/records/483/sunshine-lake-pharma-co-ltd/2eec2e95-4e99-47c8-90ae-48a090513990) — source: FDA, date: March 22, 2024
- FDA Inspection 1236240 - Sunshine Lake Pharma Co., Ltd - 2024-03-22 — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 22, 2024
- [FDA Inspection 1106395 - Sunshine Lake Pharma Co., Ltd - 2019-08-09](https://www.keypedia.com/records/fda_inspections/sunshine-lake-pharma-co-ltd/8209913c-c209-4068-8d4b-1b8fb088a353) — source: FDA, date: August 9, 2019
- [FDA Inspection 1078090 - Sunshine Lake Pharma Co., Ltd - 2019-01-25](https://www.keypedia.com/records/fda_inspections/sunshine-lake-pharma-co-ltd/64dc7b2e-06c8-40ea-8cbc-8a4f8824f3ac) — classification: Voluntary Action Indicated (VAI), source: FDA, date: January 25, 2019
- FDA Inspection 1046748 - Sunshine Lake Pharma Co., Ltd - 2018-03-16 — source: FDA, date: March 16, 2018
- [FDA Inspection 1030492 - Sunshine Lake Pharma Co., Ltd - 2017-10-19](https://www.keypedia.com/records/fda_inspections/sunshine-lake-pharma-co-ltd/b24155be-7eb1-42da-987e-8030717615c1) — classification: Voluntary Action Indicated (VAI), source: FDA, date: October 19, 2017
- [FDA Inspection 945450 - Sunshine Lake Pharma Co., Ltd - 2015-09-25](https://www.keypedia.com/records/fda_inspections/sunshine-lake-pharma-co-ltd/dd18c5f6-4e93-48e7-960b-09232f94aa39) — classification: Official Action Indicated (OAI), source: FDA, date: September 25, 2015
- [FDA Inspection 873865 - Sunshine Lake Pharma Co., Ltd - 2014-03-14](https://www.keypedia.com/records/fda_inspections/sunshine-lake-pharma-co-ltd/3a3dc39e-fc0f-4288-9afe-02b219470b3b) — classification: No Action Indicated (NAI), source: FDA, date: March 14, 2014
- FDA Inspection 728683 - Sunshine Lake Pharma Co., Ltd - 2011-04-21 — classification: Voluntary Action Indicated (VAI), source: FDA, date: April 21, 2011

## Related Companies

- [EMD Serono, Inc.](https://www.keypedia.com/companies/emd-serono-inc/6e52e7aa-a170-4208-a365-2f640b168ad3)
- [Raritan Pharmaceuticals, Inc.](https://www.keypedia.com/companies/raritan-pharmaceuticals-inc/31d76ce5-e5b2-4f61-b7b5-daa1a81f7cf0)
- [Mikart LLC](https://www.keypedia.com/companies/mikart-llc/f3303e07-0f87-4b83-a44d-0be8653c97bf)
- [Crown Laboratories Inc](https://www.keypedia.com/companies/crown-laboratories-inc/abf83f84-3545-4b6e-95fc-8294fb9e1333)
- [Tergus Pharma LLC](https://www.keypedia.com/companies/tergus-pharma-llc/430c8a0d-2cd5-47b6-91af-d5573fd6bda3)
- [Novo Nordisk A/S - G8, X9 M.FI](https://www.keypedia.com/companies/novo-nordisk-as-g8-x9-mfi/389db4db-1347-40e5-88ef-284fdcfa1a1d)
- [DSC Laboratories, Inc.](https://www.keypedia.com/companies/dsc-laboratories-inc/1cc93494-10c8-4265-8ca4-7761265d1beb)
- [ABC Compounding Co., Inc.](https://www.keypedia.com/companies/abc-compounding-co-inc/ffd26af1-9fee-4ed0-acf0-9a4ac91014c2)
- [Novo Nordisk Pharmaceutical Industries LP](https://www.keypedia.com/companies/novo-nordisk-pharmaceutical-industries-lp/6bd6ea0d-568a-4f97-ba33-f6bbab29a175)
- [Vils Pharma Coating, LLC](https://www.keypedia.com/companies/vils-pharma-coating-llc/fafd512e-c895-4c48-92b7-b71a8c518d36)

## Related Officers

- [investigator](https://www.keypedia.com/people/ephrem-hunde/3c582fce-ff16-49e8-9594-34d19b7c524e)
- [ Drug Investigator](https://www.keypedia.com/people/tekalign-wondimu/3b80e5c8-4062-4e1d-8ddd-b1afa2616dec)